Nikhita Bolar1, Lut Van Laer, Bart L Loeys. 1. Laboratory for Aneurysmal Disease Research, Center for Medical Genetics, University of Antwerp and Antwerp University Hospital, Antwerp, Belgium.
Abstract
PURPOSE OF REVIEW: Although historically Marfan syndrome (MFS) has always been considered as a condition caused by the deficiency of a structural extracellular matrix protein, fibrillin-1, the study of Marfan mouse models and Marfan-related conditions has shifted our current understanding to a pathogenic model that involves dysregulation of the cytokine-transforming growth factor beta (TGF-β) signaling. RECENT FINDINGS: In this review, we focus on the impact of the revised MFS clinical diagnostic criteria. We discuss lessons that have been learned from molecular findings in relevant Marfan-related conditions, such as sporadic thoracic aortic aneurysm/dissection, stiff skin syndrome, acromelic dysplasias and Loeys-Dietz syndrome. We explore the latest insights into the role of the alternative TGF-β signaling pathways in MFS pathogenesis. Finally, we give an update on the current and future treatment strategies. SUMMARY: The recent insights into the pathogenesis of MFS and related disorders have offered a prime example of translational medicine with immediate bridge between molecular findings and therapeutic options.
PURPOSE OF REVIEW: Although historically Marfan syndrome (MFS) has always been considered as a condition caused by the deficiency of a structural extracellular matrix protein, fibrillin-1, the study of Marfan mouse models and Marfan-related conditions has shifted our current understanding to a pathogenic model that involves dysregulation of the cytokine-transforming growth factor beta (TGF-β) signaling. RECENT FINDINGS: In this review, we focus on the impact of the revised MFS clinical diagnostic criteria. We discuss lessons that have been learned from molecular findings in relevant Marfan-related conditions, such as sporadic thoracic aortic aneurysm/dissection, stiff skin syndrome, acromelic dysplasias and Loeys-Dietz syndrome. We explore the latest insights into the role of the alternative TGF-β signaling pathways in MFS pathogenesis. Finally, we give an update on the current and future treatment strategies. SUMMARY: The recent insights into the pathogenesis of MFS and related disorders have offered a prime example of translational medicine with immediate bridge between molecular findings and therapeutic options.
Authors: Yanireth Jimenez; Cesar Paulsen; Eduardo Turner; Sebastian Iturra; Oscar Cuevas; Guillermo Lay-Son; Gabriela M Repetto; Marcelo Rojas; Juan F Calderon Journal: Genes (Basel) Date: 2022-06-08 Impact factor: 4.141
Authors: Carl Friedrich Classen; Vera Riehmer; Christina Landwehr; Anne Kosfeld; Stefanie Heilmann; Caroline Scholz; Sarah Kabisch; Hartmut Engels; Sascha Tierling; Miroslav Zivicnjak; Frank Schacherer; Dieter Haffner; Ruthild G Weber Journal: Hum Genet Date: 2013-04-04 Impact factor: 4.132
Authors: Dmitrij Achelrod; Carl Rudolf Blankart; Roland Linder; Yskert von Kodolitsch; Tom Stargardt Journal: Orphanet J Rare Dis Date: 2014-06-23 Impact factor: 4.123
Authors: Kshemendra Senarath-Yapa; Shuli Li; Nathaniel P Meyer; Michael T Longaker; Natalina Quarto Journal: Int J Mol Sci Date: 2013-03-15 Impact factor: 5.923